Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials

Shift in focus for BI 409306 (PDE9 Inhibitor) from Alzheimer's disease (AD) to schizophrenia after Phase II topline results in AD became available Research continues as planned with BI 409306 in relapse prevention in schizophrenia and in prevention of f... Biopharmaceuticals, Neurology Boehringer Ingelheim, Alzheimer's disease, GlyT1 inhibitor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news